AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02134860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
Study NCT01278381 — intervention group
Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Resection of pancreatic lesion
Study NCT03711747 — intervention group
Intervention type: PROCEDURE
Intervention: Osteochondral allograft ankle
Description: Open osteochondral allograft to replace the cartilage that is grade four on the tibia and/or talus
Study NCT00578448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: IV infusion
Study NCT02279472 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia
Description: All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
Study NCT06192875 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT00883129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
Study NCT00883129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
Study NCT00883129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
Study NCT00862667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: PF-00241939 300ug using Inhaler A
Study NCT00862667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: PF-00241939 300ug using Inhaler B
Study NCT00862667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: PF-00241939 300ug using Inhaler C
Study NCT02203773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be administered orally twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
Study NCT02203773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
Study NCT02203773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
Study NCT02203773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
Study NCT02262572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan /HCTZ - compression tablet (DC)
Study NCT02262572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan /HCTZ - dry granulation tablet (DG)
Study NCT02262572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan /HCTZ - present commercial formulation
Study NCT01756586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01756586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Control
Study NCT01756586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Control
Study NCT01700686 — intervention group
Intervention type: OTHER
Intervention: Meal test and dexa scan
Description: Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
Study NCT04719208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water (E) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
Study NCT04719208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (A) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
Study NCT04719208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (B) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
Study NCT04719208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Betadine (C) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
Study NCT04719208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol mouthwash (Listerine) (D) Mouth rinse with the solution provided
Description: Subject will be asked to perform a simple mouth rinse for 2 minutes with one of the 5 mouth washes to be tested.
Study NCT02714413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-allulose
Description: Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
Study NCT02714413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose
Description: All subjects will receive a standardized oral sucrose load of 50 gms
Study NCT02714413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sucrose
Description: All subjects will receive a standardized oral sucrose load of 50 gms
Study NCT02714413 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
Study NCT01153659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3810
Description: RAB ER 50 mg capsule once per day on Days 1-5
Study NCT01153659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aciphex (rabeprazole)
Description: Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
Study NCT02332174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rufinamide
Description: comparison of different doses, sex and medication conditions
Study NCT03862183 — intervention group
Intervention type: OTHER
Intervention: continuing medical education program
Description: educating all the involved doctor the same medical knowledge on hypertension control
Study NCT01168726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Behavioral Strategies
Description: Personalized feedback on use of protective behavioral strategies.
Study NCT01168726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Description: Personalized feedback on how one's own drinking compares to relevant norms.
Study NCT01168726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol Education
Description: Educational information about harms associated with heavy drinking.
Study NCT04664374 — intervention group
Intervention type: OTHER
Intervention: MyMood
Description: Users will use the MyMood tool. Each MyMood session consists of a brief survey, followed by a few psycho-educational 'tips'(targeted psycho-educational interventions received from time to time based on symptom severity reports as determined by the software algorithm).
Study NCT03943641 — intervention group
Intervention type: OTHER
Intervention: This is not an intervention study
Description: This study is based on retrospective analysis of linked routinely-collected healthcare data
Study NCT03738488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printing + images
Description: To perform a surgery planification with the combination of the images available and the 3D biomodel in terms of: anticipation of potential complications and the human resources and necessary materials
Study NCT03738488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Images
Description: To perform a surgery planification with the images available in terms of: anticipation of potential complications and the human resources and necessary materials
Study NCT01787630 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: Injection in connection with ultrasound
Study NCT02929030 — intervention group
Intervention type: DEVICE
Intervention: Nano
Description: The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
Study NCT01126723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
Study NCT01126723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education-Control
Description: The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
Study NCT02677194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LED
Description: There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
Study NCT02677194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control device
Description: Device without any LED exposition
Study NCT03293030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Dupilumab treatment
Study NCT03584269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LTOT
Description: Long term oxygenatory tyherapy without NIV
Study NCT00658281 — intervention group
Intervention type: PROCEDURE
Intervention: CBCT Scan
Description: Cone Beam Computed Tomography (CBCT) scan performed once a week.
Study NCT00658281 — intervention group
Intervention type: PROCEDURE
Intervention: OBI KV Imaging
Description: On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
Study NCT02089061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-919373
Study NCT02089061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT02089061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study NCT04172688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic oligofructose-enriched inulin
Description: Synergy1
Study NCT00378014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Description: Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
Study NCT00378014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basiliximab
Description: All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
Study NCT00378014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: basiliximab
Description: All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
Study NCT00378014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CNI
Description: Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
Study NCT04172688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo maltodextrin
Description: Equicaloric dose of maltodextrin
Study NCT01562275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: multiple doses
Study NCT00378014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNI
Description: Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
Study NCT02965612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injex
Description: administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
Study NCT02965612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCIT
Description: administration of Specific Immunotherapy (ITS) via traditional subcutaneous
Study NCT01562275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: multiple doses
Study NCT01153659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nexium (esomeprazole)
Description: Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
Study NCT03722459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Fingerprinting
Description: The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
Study NCT01133366 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin sodium
Description: 25 mg of warfarin oral (single dose)
Study NCT01133366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium; warfarin sodium
Description: 200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
Study NCT02392377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV or IVPB
Study NCT02392377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV or IVPB
Study NCT02392377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02392377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02392377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02392377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02392377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo esophagectomy
Study NCT02392377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00807859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab
Description: AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
Study NCT00807859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 30 mg/kg, Capecitabine and Lapatinib
Description: AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
Study NCT00807859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 10 mgkg, Paclitaxel and Trastuzumab
Description: AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
Study NCT00807859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Description: AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
Study NCT00066859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft 50 mg
Description: Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
Study NCT00066859 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: St. John's Wort 600 mg
Description: St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
Study NCT01852786 — intervention group
Intervention type: OTHER
Intervention: Contraceptives, Oral, Combined
Description: • The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
Study NCT01852786 — intervention group
Intervention type: OTHER
Intervention: Controls
Description: The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
Study NCT02659657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
Study NCT04575233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic-assisted Transversus Abdominis Plane (TAP) block
Description: The anterior axillary line is used as landmarks. After insertion of the optic trocar, the peritoneum is visualized. A 14 Gauge needle is inserted 2 cm cranially respect the taken landmark through the skin until the penetration of the internal and external oblique fascias, identified as sudden lowering of resistance. A solution of 15 ml of Ropivacaine (0.2%) is then injected. The procedure is performed then 2 cm caudal to the first landmark on the same side.~The procedure is than repeated identically on the contralateral side.
Study NCT04575233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound-assisted Transversus Abdominis Plane (TAP) block
Description: Whilst the patient is in the supine position, a high frequency ultrasound probe is placed transverse to the abdominal wall between the costal margin and iliac crest. The needle is introduced in plane of the ultrasound probe directly under the probe and advanced until it reaches the plane between the internal oblique and transversus abdominis muscles. Then 15 ml of local anaesthetic solution is injected. The needle is than retracted until its tip is positioned in the fascial plane between the internal and the external oblique muscles and a second bolus of 15 ml of local anaesthetic is injected. The procedure is than repeated identically on the contralateral side.
Study NCT04575233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
Study NCT04575233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: a solution of 15 ml of Ropivacaine (0.2%) is injected for the treatment of post-operative pain after minimally invasive surgery (TAP block)
Study NCT00718627 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Heterologous Liver Cells
Description: Multiple applications of liver cell suspension for infusion
Study NCT03205839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based self-help intervention
Description: Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.~A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.~In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video.
Study NCT01258010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.